XML 94 R31.htm IDEA: XBRL DOCUMENT
v3.25.3

Equity (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Stockholders' Equity Note [Abstract] |
Summary of share-based compensation expense | Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows:
|  | Three months ended September 30, |  | Nine months ended September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Cost of products sold |  | $ | 10 |  |  | $ | 12 |  |  | $ | 43 |  |  | $ | 44 |
Research and development |  | 76 |  |  | 67 |  |  | 315 |  |  | 274 |
Selling, general and administrative |  | 123 |  |  | 102 |  |  | 440 |  |  | 429 |
Pre-tax compensation expense |  | 209 |  |  | 181 |  |  | 798 |  |  | 747 |
Tax benefit |  | (35) |  |  | (33) |  |  | (139) |  |  | (127) |
After-tax compensation expense |  | $ | 174 |  |  | $ | 148 |  |  | $ | 659 |  |  | $ | 620 |
Cash Settled Stock Based Compensation in Connection with Acquisitions | In addition to stock-based compensation expense included in the table above and in connection with the 2025 acquisition of Capstan and the 2024 acquisitions of ImmunoGen and Cerevel Therapeutics, AbbVie incurred cash-settled, post-closing expense for employee incentive awards related to these transactions, which is summarized in the table below:
|  | Three months ended September 30, |  | Nine months ended September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Cost of products sold |  | $ | — |  |  | $ | 5 |  |  | $ | — |  |  | $ | 36 |
Research and development |  | 28 |  | 58 |  | 28 |  | 184
Selling, general and administrative |  | 67 |  | 98 |  | 67 |  | 290
Total post-closing cash settled expense |  | $ | 95 |  |  | $ | 161 |  |  | $ | 95 |  |  | $ | 510 |
Summary of quarterly cash dividends | The following table summarizes quarterly cash dividends declared during 2025 and 2024:
2025 |  | 2024
Date Declared |  | Payment Date |  | Dividend Per Share |  | Date Declared |  | Payment Date |  | Dividend Per Share
10/31/25 |  | 02/17/26 |  | $ | 1.73 |  |  | 10/30/24 |  | 02/14/25 |  | $ | 1.64 |
09/05/25 |  | 11/14/25 |  | $ | 1.64 |  |  | 09/06/24 |  | 11/15/24 |  | $ | 1.55 |
06/20/25 |  | 08/15/25 |  | $ | 1.64 |  |  | 06/21/24 |  | 08/15/24 |  | $ | 1.55 |
02/13/25 |  | 05/15/25 |  | $ | 1.64 |  |  | 02/15/24 |  | 05/15/24 |  | $ | 1.55 |
Summary of changes in balances of each component of accumulated other comprehensive loss | The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2025:
(in millions) | Foreign currency translation adjustments |  | Net investment hedging activities |  | Pension and post-employment benefits |  |  |  | Cash flow hedging activities |  | Total
Balance as of December 31, 2024 | $ | (2,114) |  |  | $ | 549 |  |  | $ | (664) |  |  |  |  | $ | 304 |  |  | $ | (1,925) |
Other comprehensive income (loss) before reclassifications | 1,489 |  |  | (885) |  |  | 3 |  |  |  |  | (105) |  |  | 502 |
Net losses (gains) reclassified from accumulated other comprehensive loss | — |  |  | (85) |  |  | 2 |  |  |  |  | (68) |  |  | (151) |
Net current-period other comprehensive income (loss) | 1,489 |  |  | (970) |  |  | 5 |  |  |  |  | (173) |  |  | 351 |
Balance as of September 30, 2025 | $ | (625) |  |  | $ | (421) |  |  | $ | (659) |  |  |  |  | $ | 131 |  |  | $ | (1,574) |
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2024:
(in millions) | Foreign currency translation adjustments |  | Net investment hedging activities |  | Pension and post-employment benefits |  |  |  | Cash flow hedging activities |  | Total
Balance as of December 31, 2023 | $ | (1,106) |  |  | $ | 65 |  |  | $ | (1,488) |  |  |  |  | $ | 224 |  |  | $ | (2,305) |
Other comprehensive income (loss) before reclassifications | 21 |  |  | 31 |  |  | (4) |  |  |  |  | 20 |  |  | 68 |
Net losses (gains) reclassified from accumulated other comprehensive loss | — |  |  | (70) |  |  | 19 |  |  |  |  | (46) |  |  | (97) |
Net current-period other comprehensive income (loss) | 21 |  |  | (39) |  |  | 15 |  |  |  |  | (26) |  |  | (29) |
Balance as of September 30, 2024 | $ | (1,085) |  |  | $ | 26 |  |  | $ | (1,473) |  |  |  |  | $ | 198 |  |  | $ | (2,334) |
Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss | The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:
| Three months ended September 30, |  | Nine months ended September 30,
(in millions) (brackets denote gains) | 2025 |  | 2024 |  | 2025 |  | 2024
Net investment hedging activities |  |  |  |  |  |  |
Gains on derivative amount excluded from effectiveness testing(a) | $ | (37) |  |  | $ | (32) |  |  | $ | (108) |  |  | $ | (90) |
Tax expense | 8 |  |  | 7 |  |  | 23 |  |  | 20 |
Total reclassifications, net of tax | $ | (29) |  |  | $ | (25) |  |  | $ | (85) |  |  | $ | (70) |
Pension and post-employment benefits |  |  |  |  |  |  |
Amortization of actuarial losses and other(b) | $ | 2 |  |  | $ | 8 |  |  | $ | 4 |  |  | $ | 25 |
Tax benefit | (1) |  |  | (2) |  |  | (2) |  |  | (6) |
Total reclassifications, net of tax | $ | 1 |  |  | $ | 6 |  |  | $ | 2 |  |  | $ | 19 |
Cash flow hedging activities |  |  |  |  |  |  |
Gains on foreign currency forward exchange contracts(c) | $ | (41) |  |  | $ | (19) |  |  | $ | (69) |  |  | $ | (41) |
Other(a) | (5) |  |  | (6) |  |  | (15) |  |  | (18) |
Tax expense | 8 |  |  | 5 |  |  | 16 |  |  | 13 |
Total reclassifications, net of tax | $ | (38) |  |  | $ | (20) |  |  | $ | (68) |  |  | $ | (46) |
(a) Amounts are included in interest expense, net (see Note 8). (b) Amounts are included in the computation of net periodic benefit cost (see Note 9). (c) Amounts are included in cost of products sold (see Note 8).

X
- Definition Cash Settled Stock Based Compensation in Connection with Acquisitions + References No definition available. + Details
Name: | abbv_CashSettledStockBasedCompensationInConnectionWithAcquisitionsTableTextBlock
Namespace Prefix: | abbv_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss). + References No definition available. + Details
Name: | us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 + Details
Name: | us-gaap_ScheduleOfDividendsPayableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration